Arcturus Therapeutics Holdings Inc.’s ARCT share price has surged by 6.84%, which has investors questioning if this is right ...

In a report released yesterday, Lili (Aurélie) Nsongo from Leerink Partners maintained a Hold rating on Arcturus Therapeutics ( ARCT – Research Report ), with a price target of $63.00. Discover ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Arcturus Therapeutics Holdings Inc is a biotechnology firm based in San Diego, California, specializing in the development of innovative mRNA medicines and vaccines. With a focus on addressing ...

The Japanese drugs giant Takeda and the US biotech Arcturus Therapeutics have joined the hunt for therapies for the COVID-19 coronavirus. As the infection and death count continues to rise across ...

Several pharma companies – Arcturus Therapeutics, Bayer, GSK, Moderna, Pfizer, and Sanofi - are all racing to develop mRNA influenza vaccines. GSK has teamed up with CureVac and currently has ...

1 Day ARCT 2.23% DJIA -1.33% Russell 2K 0.92% Health Care/Life Sciences -0.86% ...

1 Day ARCT -2.55% DJIA -1.73% Russell 2K -1.03% Health Care/Life Sciences 0.16% ...

March S&P 500 E-Mini futures (ESH25) are down -0.92%, and March Nasdaq 100 E-Mini futures (NQH25) are down -1.14% this morning as higher Treasury yields, trade war worries, and disappointing tech ...

**NM signifies a non meaningful value. A dash signifies the data is not available.